Sysmex Corporation (FRA:0YX)

Market Cap	4.61B -57.8%
Revenue (ttm)	2.73B +0.2%
Net Income	243.08M -22.6%
EPS	0.39 -22.5%
Shares Out	n/a
PE Ratio	18.96
Forward PE	n/a
Dividend	0.21 (3.06%)
Ex-Dividend Date	Mar 30, 2026

Volume	n/a
Average Volume	62
Open	6.91
Previous Close	7.70
Day's Range	6.91 - 6.91
52-Week Range	6.60 - 17.40
Beta	n/a
RSI	45.40
Earnings Date	May 14, 2026

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematology analyzer ProCyte Dx for Research applications, a housed in a compact body that simultaneously measures five types of leukocytes and reticulocyte co...

• Industry: Laboratory Analytical Instruments
• Founded: 1968
• Employees: 10,533
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0YX

Financial Performance

In fiscal year 2025, Sysmex's revenue was 508.64 billion, an increase of 10.21% compared to the previous year's 461.51 billion. Earnings were 53.67 billion, an increase of 8.12%.

Financial numbers in JPY